SEC Form 4 · accession 0001470831-26-000837
BridgeBio Pharma, Inc. · BBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas Trimarchi
Officer — President and CFO
Period of report
Aug 16, 2026
Accepted (ET)
Aug 18, 2026 · 6:02 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001743881
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Aug 16, 2026 | F | 22,781 | $79.86 | D | 336,529 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 41,194 shares of Common Stock underlying the Reporting Person's RSUs.
- F2Includes 116 shares of the Issuer's Common Stock acquired by the Reporting Person on August 14, 2026 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.